JP6271510B2 - 二糖合成脂質化合物およびその使用 - Google Patents

二糖合成脂質化合物およびその使用 Download PDF

Info

Publication number
JP6271510B2
JP6271510B2 JP2015505953A JP2015505953A JP6271510B2 JP 6271510 B2 JP6271510 B2 JP 6271510B2 JP 2015505953 A JP2015505953 A JP 2015505953A JP 2015505953 A JP2015505953 A JP 2015505953A JP 6271510 B2 JP6271510 B2 JP 6271510B2
Authority
JP
Japan
Prior art keywords
compound
diglycolipid
synthetic
unsubstituted alkyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015505953A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015512946A (ja
JP2015512946A5 (https=
Inventor
ショウ，ウォルター・エイ
バージェス，スティーブン・ダブリュ
リー，シェンロン
ヒックマン，デイビッド・ティー
ロペス−デベル，マリア・ピラール
Original Assignee
アバンティ・ポーラ・リピッド・インコーポレイテッド
エーシー イミューン エス．エー．
エーシー イミューン エス．エー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アバンティ・ポーラ・リピッド・インコーポレイテッド, エーシー イミューン エス．エー．, エーシー イミューン エス．エー． filed Critical アバンティ・ポーラ・リピッド・インコーポレイテッド
Publication of JP2015512946A publication Critical patent/JP2015512946A/ja
Publication of JP2015512946A5 publication Critical patent/JP2015512946A5/ja
Application granted granted Critical
Publication of JP6271510B2 publication Critical patent/JP6271510B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C07H13/06—Fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2015505953A 2012-04-12 2013-04-12 二糖合成脂質化合物およびその使用 Active JP6271510B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261623393P 2012-04-12 2012-04-12
US61/623,393 2012-04-12
US13/842,424 US9241988B2 (en) 2012-04-12 2013-03-15 Disaccharide synthetic lipid compounds and uses thereof
US13/842,424 2013-03-15
PCT/US2013/036425 WO2013155448A1 (en) 2012-04-12 2013-04-12 Disaccharide synthetic lipid compounds and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017248795A Division JP6764396B2 (ja) 2012-04-12 2017-12-26 二糖合成脂質化合物およびその使用

Publications (3)

Publication Number Publication Date
JP2015512946A JP2015512946A (ja) 2015-04-30
JP2015512946A5 JP2015512946A5 (https=) 2016-04-28
JP6271510B2 true JP6271510B2 (ja) 2018-01-31

Family

ID=49325307

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015505953A Active JP6271510B2 (ja) 2012-04-12 2013-04-12 二糖合成脂質化合物およびその使用
JP2017248795A Active JP6764396B2 (ja) 2012-04-12 2017-12-26 二糖合成脂質化合物およびその使用
JP2020091157A Active JP7189906B2 (ja) 2012-04-12 2020-05-26 二糖合成脂質化合物およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017248795A Active JP6764396B2 (ja) 2012-04-12 2017-12-26 二糖合成脂質化合物およびその使用
JP2020091157A Active JP7189906B2 (ja) 2012-04-12 2020-05-26 二糖合成脂質化合物およびその使用

Country Status (9)

Country Link
US (2) US9241988B2 (https=)
EP (2) EP3674309B1 (https=)
JP (3) JP6271510B2 (https=)
CN (2) CN104470938B (https=)
CA (1) CA2870008C (https=)
DK (1) DK3674309T3 (https=)
ES (2) ES2787876T3 (https=)
IN (1) IN2014DN09392A (https=)
WO (1) WO2013155448A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2468300T (pt) 2006-09-26 2018-01-30 Infectious Disease Res Inst Composição para vacina contendo adjuvante sintético
US9241988B2 (en) * 2012-04-12 2016-01-26 Avanti Polar Lipids, Inc. Disaccharide synthetic lipid compounds and uses thereof
KR102136433B1 (ko) 2012-05-16 2020-07-22 이뮨 디자인 코포레이션 Hsv-2 백신
US9149522B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9504743B2 (en) 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149521B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US20150086592A1 (en) 2013-09-25 2015-03-26 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
RU2694367C2 (ru) * 2014-09-12 2019-07-12 Бестевил Холдинг Б.В. Способы получения адъювантных виросом и адъювантные виросомы, получаемые указанными способами
EP3270962A4 (en) * 2015-03-17 2018-08-22 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
EP3069729A1 (en) * 2015-03-17 2016-09-21 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
WO2020055503A1 (en) 2018-09-14 2020-03-19 Massachusetts Institute Of Technology Nanoparticle vaccine adjuvant and methods of use thereof
CA3118692A1 (en) 2018-11-06 2020-05-14 Alsatech, Inc. Cell-based gene therapy for neurodegenerative diseases
WO2020109365A1 (en) 2018-11-29 2020-06-04 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
US12533418B2 (en) 2019-11-22 2026-01-27 Glaxosmithkline Biologicals Sa Dosage and administration of a bacterial saccharide glycoconjugate vaccine
WO2023114570A1 (en) 2021-12-19 2023-06-22 Massachusetts Institute Of Technology Compositions and methods for long-lasting germinal center responses to a priming immunization
JP2025531282A (ja) 2022-09-21 2025-09-19 ウィスコンシン アルムニ リサーチ ファンデイション がん治療の治療効果を高めるための組成物および方法
WO2024151642A1 (en) * 2023-01-09 2024-07-18 University Of Maryland, Baltimore Engineered anti-nociceptive-los competitive tlr4 ligands and methods for treating pain while maintaining immunosufficiency

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5066794A (en) 1984-08-24 1991-11-19 Daiichi Pharmaceutical Co., Ltd. Process for preparing a disaccharide derivative
GR860379B (en) * 1985-02-22 1986-06-11 Akzo Nv Novel disaccharide and trisaccharide derivatives of the lipid a type
JP2535048B2 (ja) 1988-02-29 1996-09-18 第一製薬株式会社 新規ジサッカライド誘導体及びその塩
JPH06206893A (ja) * 1992-09-07 1994-07-26 Suntory Ltd 新規なジサッカライド誘導体
AU679970B2 (en) 1993-09-07 1997-07-17 Suntory Limited Novel disaccharide derivative
PT729473E (pt) * 1993-11-17 2001-02-28 Deutsche Om Arzneimittel Gmbh Dissacaridos de glucosamina metodo para a sua preparacao composicao farmaceutica contendo os mesmos e sua utilizacao
JPH10152497A (ja) * 1996-09-30 1998-06-09 Otsuka Pharmaceut Factory Inc ヘリコバクター・ピロリのリピドａ
HK1039072A1 (zh) * 1998-05-07 2002-04-12 科里克萨有限公司 佐剂组合物及其使用方法
JP2002520373A (ja) * 1998-07-14 2002-07-09 アメリカン・サイアナミド・カンパニー モノホスホリルリピドａを含有するアジュバントおよびワクチン組成物
US20020022032A1 (en) * 1999-04-23 2002-02-21 Curry Patrick Mark Immuno-adjuvant PDT treatment of metastatic tumors
ES2370262T3 (es) 1999-11-15 2011-12-14 Oncothyreon Inc. Análogos del lípido a sintéticos y sus utilizaciones.
CN1907289A (zh) * 2000-05-19 2007-02-07 科里克萨有限公司 用单糖和二糖类化合物预防和治疗传染病和其他疾病的方法
EP2000144A1 (en) * 2000-05-19 2008-12-10 Corixa Corporation Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with mono-and disaccharide-based compounds
US20030031684A1 (en) * 2001-03-30 2003-02-13 Corixa Corporation Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
GB0420634D0 (en) * 2004-09-16 2004-10-20 Glaxosmithkline Biolog Sa Vaccines
US7622128B2 (en) * 2005-12-13 2009-11-24 University Of Washington Porphyromonas gingivalis 1435/1449 LPS as an immune modulator
WO2008059307A2 (en) * 2006-11-16 2008-05-22 Om Pharma Functionalized beta 1,6 glucosamine disaccharides and process for their preparation
WO2009035528A2 (en) * 2007-09-07 2009-03-19 University Of Georgia Research Foundation, Inc. Synthetic lipid a derivative
PL2222710T3 (pl) * 2007-12-24 2017-01-31 Id Biomedical Corporation Of Quebec Rekombinowane antygeny rsv
US9241988B2 (en) * 2012-04-12 2016-01-26 Avanti Polar Lipids, Inc. Disaccharide synthetic lipid compounds and uses thereof

Also Published As

Publication number Publication date
EP2836499A4 (en) 2015-11-25
CA2870008A1 (en) 2013-10-17
JP2015512946A (ja) 2015-04-30
ES2992314T3 (es) 2024-12-11
CN107412766A (zh) 2017-12-01
CA2870008C (en) 2021-05-04
EP2836499B1 (en) 2020-02-26
US9241988B2 (en) 2016-01-26
JP7189906B2 (ja) 2022-12-14
WO2013155448A1 (en) 2013-10-17
JP6764396B2 (ja) 2020-09-30
JP2020147579A (ja) 2020-09-17
JP2018070652A (ja) 2018-05-10
HK1207383A1 (en) 2016-01-29
CN104470938B (zh) 2017-07-28
US10143744B2 (en) 2018-12-04
CN104470938A (zh) 2015-03-25
IN2014DN09392A (https=) 2015-07-17
EP3674309B1 (en) 2024-09-11
EP2836499A1 (en) 2015-02-18
ES2787876T3 (es) 2020-10-19
US20160136271A1 (en) 2016-05-19
DK3674309T3 (da) 2024-11-25
US20130273149A1 (en) 2013-10-17
EP3674309A1 (en) 2020-07-01

Similar Documents

Publication Publication Date Title
JP7189906B2 (ja) 二糖合成脂質化合物およびその使用
US9518078B2 (en) Disaccharide synthetic lipid compounds and uses thereof
JP7386536B2 (ja) アルキル鎖修飾イミダゾキノリンｔｌｒ７／８アゴニスト化合物およびその使用
JPS6238330B2 (https=)
ES2389080T3 (es) Fármaco que presenta un ligando de células reguladoras contenido en el liposoma
US4117113A (en) Immunological preparations
US9827260B2 (en) Composition for buffered aminoalkyl glucosaminide phosphate compounds and its use for enhancing an immune response
WO2016176558A1 (en) Adjuvant particles comprising adenosine receptor antagonists
JP2016531853A (ja) 抗原特異的免疫原性を低減するための組成物及び方法
US20220257752A1 (en) New use of cyclic dinucleotides
WO2008026781A1 (en) Reverse targeting lipid vesicle
CN118843455A (zh) 免疫原性mRNA递送媒介物
US20170349618A1 (en) Disaccharide synthetic lipid compounds and uses thereof
HK1207383B (en) Disaccharide synthetic lipid compounds and uses thereof
US20110104248A1 (en) Liposomes and immunopotentiating compositions containing the same
JP4092367B1 (ja) リポソームおよびこれを含む免疫賦活活性用組成物。
WO2025157144A1 (zh) 经黏膜给药的水包油乳液
TW202342094A (zh) 高度活化之脂質奈米粒子
EP1933846A2 (en) Compositions comprising phosphatidic acid for treatment of eosinophilia and related disorders
Gameiro et al. Pulmonary delivery of liposome-based GST1194 conformational variants: implications for vaccine development against Schistosoma mansoni infection

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160310

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170404

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171004

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171128

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171227

R150 Certificate of patent or registration of utility model

Ref document number: 6271510

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250